全文获取类型
收费全文 | 3080篇 |
免费 | 177篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 81篇 |
妇产科学 | 69篇 |
基础医学 | 99篇 |
口腔科学 | 22篇 |
临床医学 | 263篇 |
内科学 | 476篇 |
皮肤病学 | 14篇 |
神经病学 | 125篇 |
特种医学 | 71篇 |
外科学 | 473篇 |
综合类 | 193篇 |
一般理论 | 1篇 |
预防医学 | 821篇 |
眼科学 | 13篇 |
药学 | 387篇 |
中国医学 | 14篇 |
肿瘤学 | 136篇 |
出版年
2023年 | 44篇 |
2022年 | 67篇 |
2021年 | 117篇 |
2020年 | 131篇 |
2019年 | 168篇 |
2018年 | 166篇 |
2017年 | 126篇 |
2016年 | 98篇 |
2015年 | 104篇 |
2014年 | 229篇 |
2013年 | 321篇 |
2012年 | 162篇 |
2011年 | 167篇 |
2010年 | 117篇 |
2009年 | 167篇 |
2008年 | 176篇 |
2007年 | 141篇 |
2006年 | 114篇 |
2005年 | 114篇 |
2004年 | 79篇 |
2003年 | 73篇 |
2002年 | 63篇 |
2001年 | 54篇 |
2000年 | 52篇 |
1999年 | 50篇 |
1998年 | 26篇 |
1997年 | 35篇 |
1996年 | 18篇 |
1995年 | 13篇 |
1994年 | 17篇 |
1993年 | 9篇 |
1992年 | 8篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 5篇 |
1988年 | 5篇 |
1987年 | 10篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 7篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有3284条查询结果,搜索用时 15 毫秒
1.
Mariángeles González Fernández Elena Villamañán Inmaculada Jiménez-Nácher Francisco Moreno Chamaida Plasencia Francisco Gayá Alicia Herrero Alejandro Balsa 《Reumatología clinica》2021,17(6):335-342
ObjectiveTo assess the evolution of cost per patient/year and the cost per patient/year/drug in patients with rheumatoid arthritis (RA) receiving biological treatments. To analyze and quantify the factors influencing this evolution, such as the optimization of the biological drugs, the use of biosimilars, and official discounts and discounts obtained after negotiated procedures. In addition, to assess specific clinical parameters of disease activity in these patients.MethodsRetrospective, observational study conducted in a Spanish tertiary hospital. Adult patients diagnosed with RA under treatment from 2009 to 2017 were included.Results320, 270 and 389 patients were included in 2009, 2013 and 2017, respectively. The patient/year cost decreased from 10,789€ in 2009, 7491€ in 2013 to 7116€ in 2017. In 2017, due to the established competition, discounts of 14% and 29.5% were achieved on etanercept and its biosimilar; 11.5%, 17.8%, 17.9%, 17.3% on adalimumab, certolizumab, golimumab and tocilizumab IV respectively, and 24.6% and 43.1% on infliximab and its biosimilar. The percentage of patients optimized in 2017 was 35.2%. The annual saving in 2017 was 1,288,535€ (830,000€ due to dose optimization and/or administration regimens, 249,666€ corresponding to 7.5% of the official discount and 208,868€ after negotiated procedures).ConclusionThe annual cost per patient in RA decreased considerably due to different factors, such as discounts on the purchase of drugs due to official discounts and negotiated procedures, together with the optimization of therapies, the latter being the factor that contributed most to this decrease. 相似文献
2.
3.
《Seminars in Fetal & Neonatal Medicine》2022,27(3):101336
ObjectiveThis study aimed to systematically review the current literature on the economic costs of micro preemie as well as evidence on the cost-effectiveness of interventions to improve outcomes for micro preemie babies with a birth weight of ≤500 g.MethodWe searched MEDLINE, CINAHL, Scopus, ECONLIT, Business Source Premier and Cochrane Library for studies reporting costs of micro preemie from January 2000. Costs were inflated to 2019 United States dollars (US$). All full-text articles were assessed for eligibility and a quality assessment of included articles was conducted using the Drummond and the Larg and Moss checklists.ResultsThe search identified three studies that met the inclusion criteria; two cost-of-illness studies and one cost-effectiveness study. Across studies, the mean healthcare spending per micro preemie survivor (in 2019 US$) ranged from US$61,310 (birth admission) to US$263,958 (inpatient and outpatient for the first six months of life). One modelling study reported exclusive human milk diet for micro preemies at birth was more cost-effective compared to the standard approach with cow milk diet from the third-party payer and societal perspectives.ConclusionDespite significant advances in perinatal care and expanded access to life-saving equipment to improve survival outcomes of micro preemie, there remains a paucity of research on economic costs associated with these babies. No study has utilised quality-adjusted life-years as an outcome measure. Given the chronic conditions and long-term neurologic disability associated with micro preemie survivors, an estimate of the lifetime cost to the individual, healthcare providers and society would provide a benchmark of the potential cost-savings that could accrue from cost-effective interventions to improve the survival rate of micro preemies. 相似文献
4.
《Journal of neonatal nursing : JNN》2020,26(2):120-122
Background and objectiveReports on expenses to families of extreme preterm babies are scarce. Charges may vary based on regional socio-economic conditions. Systematic auditing of hospital care costs helps families develop a tangible feel of expected expenses. It also allows the medical team to identify areas where costs can be reduced. We studied expenses borne by the families towards care of an extreme preterm neonate during hospital stay.MethodsNeonates who were delivered <28 weeks and who completed care till discharge in the unit were included. The bills to the family were retrospectively analysed.ResultsThe median per day charge borne by the family was USD 107.4 (IQR 94.6–135.5). The median total cost to the patient was USD 9446.5. Maximum proportion of the costs were towards nursing charges.ConclusionsThe average per day charges was USD 107.4 (IQR 94.6–135.5). Stringent efforts should be made by the health care teams to optimise the costs to families. Neonatal intensive care needs to be commercially viable as well. 相似文献
5.
6.
《Journal of the American College of Radiology》2020,17(12):1563-1570
ObjectiveTo use time-driven activity-based costing to compare the costs of pathways for evaluating suspected pediatric midgut volvulus using either fluoroscopic upper gastrointestinal examination (UGI) or focused abdominal ultrasound (US).MethodsProcess maps were created through patient shadowing, medical record review, and frontline staff interviews. Using time-driven activity-based costing methodology, practical capacity cost rates were calculated for personnel, equipment, and facility costs. Supply costs were included at institutional purchase prices. The cost of each process substep was determined by multiplying step-specific capacity costs by the median time required for each step, and substep costs were summed to generate total pathway cost. Multivariate sensitivity analyses were performed applying minimum and maximum labor costs. Assuming UGI would be used to troubleshoot nondiagnostic US, a break-even analysis was performed to determine the cost impact of varying frequencies of UGI on the total cost of the US-based pathway.ResultsProcess maps were created from 105 (48 girls, 57 boys) patient encounters. Base case pathway times were 90 min (UGI) and 55 min (US). Base case cost for UGI was $282.74 (range: $170.86-$800.82) when performed by a radiology practitioner assistant and $545.66 (range: $260.97-$1,974.06) when performed by a radiologist. Base case cost for US was $155.67 (range: $122.94-$432.29) when performed by a sonographer and $242.64 (range: $147.46-$1,330.05) when performed by a radiologist. For a US-based pathway, the total cost break-even pathway mix (percent UGI required for troubleshooting) was 57%.ConclusionUS can be a faster and less costly alternative to UGI in pediatric patients with suspected midgut volvulus. 相似文献
7.
Xiuhua Weng Shaohong Luo Shen Lin Lixian Zhong Meiyue Li Rao Xin Pinfang Huang Xiongwei Xu 《Oncology research》2020,28(2):117-125
To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed
to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE-
042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival
functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios
(ICERs) were computed as primary output indicators. The impact of different PD-L1 expression levels
on ICER was also evaluated. One-way and probabilistic sensitivity analyses were performed to assess the
model uncertainty. Compared with chemotherapy, patients treated with pembrolizumab provided an additional 1.13, 1.01, and 0.59 QALYs in patients with PD-L1 expression levels of ≥50%, ≥20%, and ≥1%,
with corresponding incremental cost of $53,784, $47,479, and $39,827, respectively. The resultant ICERs
of pembrolizumab versus chemotherapy were $47,596, $47,184, and $68,061/QALY, in three expression
levels of PD-L1, respectively, all of which did not exceed the WTP threshold of 180,000/QALY. Probability
sensitivity analysis outcome supported that pembrolizumab exhibited evident advantage over chemotherapy
to be cost-effective. One-way sensitivity analysis found that ICERs were most sensitive to utility value of
pembrolizumab in progression survival state. All the adjustment of parameters did not qualitatively change
the result. For treatment-naive, metastatic NSCLC patients with PD-L1+, pembrolizumab was estimated
to be cost-effective compared with chemotherapy for all PD-L1 expression levels at a WTP threshold of
$180,000/QALY in the context of the US health care system. 相似文献
8.
9.
Lisa J. McGarry Yaozhu J. Chen Shibani Pokras Catherine R. Taylor Julie Munakata 《Current medical research and opinion》2016,32(2):289-299
Objective:To assess the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), by assessing all-cause health care resource use (HCRU) and costs in the year after treatment failure by line of therapy (LOT; 1L/2L/3L) using real-world data.Methods:Treatment episodes initiating a TKI of interest (index TKI) during June 2008–December 2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120 days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of?≥?60 days), and with 1 year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used in the pre-index. All-cause HCRU and costs (2012 USD) in the 1 year post-failure were assessed by LOT, and the comparisons between 1L and 2L failures were also adjusted using multivariate generalized linear models (GLMs) to control for underlying differences.Results:A total of 706 episodes were identified (518 1L; 180 2L; 8 3L). Unadjusted HCRU over 1 year post-failure increased significantly. This was accompanied by a significant increase in unadjusted mean costs for 2L failures vs. 1L failures ($99,624 vs. $78,667, p?=?0.021, Δ$20,957). Following the adjustment using GLMs, adjusted mean costs were 38% higher (95% CI 1.14–1.68), driven primarily by use of medical services. In adjusted analyses, compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 1.26–1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% CI 1.16–2.64), and 73% higher medical costs (95% CI 1.31–2.29). Medical costs comprised a greater proportion of total costs in 2L vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly.Conclusions:The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure. 相似文献
10.